Table 2a. Antibody Performance, Weeks 3 to 5 – IgM

IgM	Week 3			Week 4			Week 5		
Sensitivity	0.89 (95% CI: 0.82 to 0.93)			0.84 (95% CI: 0.67 to 0.93)			0.78 (95% CI: 0.73 to 0.83)		
Specificity	0.98 (95% CI: 0.97 to 0.99)								
Outcome	**Effect per 1,000 patients tested**								
	Pre-test Probability								
	1% [a]	**10%** [b]	**40%** [c]	**1%** [a]	**10%** [b]	**40%** [c]	**1%** [a]	**10%** [b]	**40%** [c]
True positives (patients with COVID-19)	9 (8 to 9)	89 (82 to 93)	356 (328 to 372)	8 (7 to 9)	84 (67 to 93)	336 (268 to 372)	8 (7 to 8)	78 (73 to 83)	312 (292 to 332)
False negatives (patients incorrectly classified as not having COVID-19)	1 (1 to 2)	11 (7 to 18)	44 (28 to 72)	2 (1 to 3)	16 (7 to 33)	64 (28 to 132)	2 (2 to 3)	22 (17 to 27)	88 (68 to 108)
Quality of the evidence	14 studies, 1730 patients ⊕◯◯◯ VERY LOW [d,e,f]			6 studies, 619 patients ⊕◯◯◯ VERY LOW [d,e,f]			2 studies, 260 patients ⊕⊕◯◯ LOW [d,e]		
	pre-test probability of 1% [a]			**pre-test probability of 10%** [b]			**pre-test probability of 40%** [c]		
True negatives (patients without COVID-19)	970 (960 to 980)			882 (873 to 891)			588 (582 to 594)		
False positives (patients incorrectly classified as having COVID-19)	20 (10 to 30)			18 (9 to 27)			12 (6 to 18)		
Quality of Evidence	21 studies, 7165 patients ⊕⊕⊕◯ MODERATE[d]								

a. Typically seen in general population in areas that are not hotspots
b. Typically seen in general population in high risk populations
c. Typically seen in general population in exposed and nursing homes
d. The case-control design leads to a serious risk of bias
e. Unexplained inconsistency observed with considerably variable sensitivity. Sensitivity Ranges: C3: 0.55-1.00, C4: 0.36-1.00, C5: 0.76-0.92.
f. Considering the Upper vs Lower limits of the sensitivity's confidence interval would lead to different clinical decisions.